Spiral aortoplasty for dilated ascending aorta: a new technique for high-risk patients with combined procedures

Rakan I. Nazer

Abstract
Concomitant replacement of the ascending aorta with the aortic valve in patients who have left ventricular dysfunction might carry high operative risks. Performing the conservative reduction aortoplasty was shown to have less complications in such patients. When combined with other concomitant cardiac procedures, the newly described “spiral” aortoplasty technique in this series allows for a multilplanar wall tension reduction in moderately dilated ascending aorta.

Keywords: Aorta, Aortoplasty, Bicuspid valve

Introduction
Ascending aorta dilatation is sometimes concomitantly associated with aortic valve disease. It is generally recommended to surgically intervene on the ascending aorta once the maximum diameter is above 4.5 cm in the setting of other surgical cardiac procedures [1]. This is to avoid the possible risk of future aorta dilatation or the possibility of aortic dissection and rupture [2]. The dilated ascending aorta can be surgically addressed by radical ascending aorta replacement with a tube graft or by the less popular and more conservative reduction aortoplasty, with or without external wrapping [3]. The following sections describes a modified reduction aortoplasty with concomitant cardiac procedures in high risk patients.

Patients
A series of 9 patients are described after local ethical board approval with individual consent for every patient in the series. They had a dilated ascending aortas (4.5 cm to < 5.0 cm) in the setting of concomitant aortic valve replacement with left ventricular dysfunction from July 2016 to December 2018 at our institution. Some patients required additional mitral repair and/or coronary bypass grafting (CABG). All patients successfully underwent “spiral” aortoplasty to reduce the aortic diameter. The ascending aorta was measured for each patient on follow-up at the level of the mid ascending aorta with the use of CT angiography (Table 1).

Technique
The heart was accessed through a median sternotomy and cardiopulmonary bypass was initiated via central cannulation. The arterial cannula was inserted in the proximal aortic arch. Prior to applying the cross clamp, an umbilical tape was looped around the backside of the ascending aorta and was lifted before applying the cross clamp to ensure the clamp captured the entire aortic wall. The clamp was positioned as high as possible in the ascending aorta. An oblique aortotomy was performed in the middle of the anterior segment of the ascending aorta and was spirally extended downward and laterally toward the non-coronary sinus, stopping at the aortic annulus, and superiorly toward the left shoulder up to the bifurcation of the pulmonary artery. The aortic valve was replaced through this access. Concomitant procedures such as distal coronary grafts and/or mitral repair were performed prior to the aortic procedure. The aortotomy closure was sandwiched between 2 strips of Teflon felt and sutured together using a double closure technique. The Suture incorporated 0.5 cm of aortic tissue on either side during closure in order to reduce the aortic size by 1 cm. (Fig. 1).
| Series no. | Age / Sex | AAD before surgery | LV EF | Diagnosis | Bicuspid aortic valve | Euro Score | Procedure | Follow-up time | Condition on follow-up |
|-----------|-----------|---------------------|-------|-----------|----------------------|------------|-----------|---------------|------------------------|
| 1         | 53 M      | 4.7 cm              | 30%   | CHF       | +                    | 5.45%      | Aortoplasty | 30 months     | Stable. AAD 3.8 cm     |
|           |           |                     |       | Severe AI |                      |            | AVR (mosaic #27) |               |                        |
|           |           |                     |       | Moderate MR |                    |            | MV repair (annuloplasty #30) |               |                        |
|           |           |                     |       | Atrial fibrillation | |            | MAZE |               |                        |
|           |           |                     |       | Stroke |                      |            | LAA clot extraction and ligation |               |                        |
|           |           |                     |       | Clot in the LAA | |            |                 |               |                        |
| 2         | 70 M      | 4.5 cm              | 25%   | CHF       | +                    | 20.4%      | Aortoplasty | 28 months     | Stable. AAD 3.6 cm     |
|           |           |                     |       | Severe AI |                      |            | AVR (mosaic #27) |               |                        |
| 3         | 60 M      | 4.5 cm              | 35%   | Severe AS |                      | 17.70%     | Aortoplasty | 25 months     | Stable. AAD 3.7 cm     |
|           |           |                     |       | CAD: LAD stenosis | |            | AVR (mosaic #25) |               |                        |
|           |           |                     |       |            |                      |            | CABG: LIMA-LAD |               |                        |
| 4         | 67 M      | 4.6 cm              | 30%   | Severe AS |                      | 20.20%     | Aortoplasty | 21 months     | Stable. AAD 3.8 cm     |
|           |           |                     |       |            |                      |            | AVR (mosaic #21) |               |                        |
|           |           |                     |       |            |                      |            | MV repair (annuloplasty #28) |               |                        |
|           |           |                     |       |            |                      |            | CABG: LIMA-LAD |               |                        |
| 5         | 62 F      | 4.5 cm              | 40%   | Severe AS |                      | 9.50%      | Aortoplasty | 17 months     | Stable. AAD 3.3 cm     |
|           |           |                     |       |            |                      |            | AVR (mosaic #23) |               |                        |
|           |           |                     |       |            |                      |            | CABG: SVG-RCA |               |                        |
| 6         | 55 M      | 4.8 cm              | 15%   | Severe AI |                      | 24.00%     | Aortoplasty | 16 months     | Stable. AAD 3.9 cm     |
|           |           |                     |       | CAD: 3 vessel disease | |            | AVR (mosaic #27) |               |                        |
|           |           |                     |       |            |                      |            | CABG: LIMA-LAD, SVG-OM, SVG-PDA |               |                        |
| 7         | 50 M      | 4.8 cm              | 20%   | CHF       | +                    | 84.70%     | Aortoplasty | 14 months     | AAD 3.7 cm. The patient presented with aortic prosthesis endocarditis and aortic root abscess 10 months after the first operation. He underwent redo surgery with aortic annulus reconstruction and AVR. The patient was discharged on chronic dialysis and died 4 months later due to refractory heart failure. |
|           |           |                     |       | Severe AI |                      |            | AVR (mosaic #27) |               |                        |
|           |           |                     |       | Severe MR |                      |            | MV repair (annuloplasty #30) |               |                        |

Table 1: Case series of 9 patients who underwent “spiral” aortoplasty with concomitant aortic valve replacement +/- CABG +/- mitral valve repair.
Table 1  Case series of 9 patients who underwent "spiral" aortoplasty with concomitant aortic valve replacement +/- CABG +/- mitral valve repair (Continued)

| Series no. | Age / Sex | AAD before surgery | LV EF | Diagnosis | Bicuspid aortic valve | Euro Score | Procedure | Follow-up time | Condition on follow-up |
|------------|-----------|---------------------|-------|-----------|-----------------------|------------|-----------|-----------------|------------------------|
| 8          | 66 M      | 4.6 cm              | 40%   | Severe AI |                       | 12.80%     | Aortoplasty | 6 months       | Stable. AAD 3.5 cm     |
|            |           |                     |       |           | CAD: RCA total occlusion |            | AVR (mosaic #25) |                |                        |
| 9          | 72 M      | 4.5 cm              | 40%   | Severe AS | +                     | 11.00%     | Aortoplasty | 4 months       | Stable. AAD 3.5 cm     |
|            |           |                     |       |           | CAD: 3 vessel disease |            | AVR (mosaic #23) |                |                        |
|            |           |                     |       |           | CABG: SVG-PDA          |            |            |                |                        |
|            |           |                     |       |           | CABG: LIMA-LAD, SVG-OM, SVG-PDA | | | | |

AA ascending aorta, AAD ascending aorta diameter, AI aortic regurgitation, AS aortic stenosis, AVR aortic valve replacement, CABG coronary artery bypass grafting, CAD coronary artery disease, CHF congestive heart failure, LAA left atrial appendage, LAD left anterior descending, LIMA left internal mammary, LV EF left ventricular ejection fraction, MR mitral regurgitation, OM obtuse marginal, RCA right coronary artery, PDA posterior descending artery, SVG saphenous vein graft.
Comments

Fusiform ascending aorta aneurysm is commonly observed in patients with aortic valve disease, particularly in those with a bicuspid aortic valve. The dilatation is likely due to intrinsic factors harbored within the connective tissue of the aortic wall. The multiplanar dilatation causes elongation and circumferential expansion of the aorta. Previously described reduction aortoplasty techniques primarily reduce the aortic diameter and wall tension at a single plane in the mid-anterior wall of the ascending aorta [4]. The technique described in this series has the same advantages of other described aortoplasty approaches in high-risk patients with the added advantage of reducing the wall tension and size along the circumferential and longitudinal planes. External wrapping was avoided because of the reported risks of “under-the-wrap” aortic atrophy and rupture, wrap migration, and the need to construct proximal coronary anastomosis in the ascending aorta. Bicuspid aortic valve was present in over half of the series. All patients showed an approximately 1-cm reduction of the mid-ascending aortic diameter on echocardiographic and tomographic follow-up. This technique should not be used in patients with dilated aortic root, ascending aortas with a diameter of >5.0 cm, in patients with acute aortic dissection, or in patients with syndromic connective tissue disorders such as Marfan’s syndrome. The series is limited by its small size, short follow-up, and the potential risk for redilatation of the ascending aorta.

In summary, this series describes a limited number of high risk patients who successfully underwent concomitant aortic valve replacement with reduction aortoplasty and other added procedures. The spiral aortoplasty technique has the advantage of multiplanar aortic size reduction without the need to perform the more radical ascending aorta replacement in moderately dilated ascending aorta.

Abbreviations

AA: Ascending aorta; AAD: Ascending aorta diameter; AI: Aortic regurgitation; AS: Aortic stenosis; AVR: Aortic valve replacement; CABG: Coronary artery bypass grafting; CAD: Coronary artery disease; CHF: Congestive heart failure; LAA: Left atrial appendage; LAD: Left anterior descending; LIMA: Left internal mammary; LV EF: Left ventricular ejection fraction; MR: Mitral regurgitation; OM: Obtuse marginal; PDA: Posterior descending artery; RCA: Right coronary; SVG: Saphenous vein graft

Acknowledgments

This project was supported by College of Medicine Research Centre, Deanship of Scientific Research, King Saud University.

Author’s contribution

RIN MD, conceived, performed and wrote the manuscript. The author read and approved the final manuscript.

Funding

None.

Availability of data and materials

Data related to the manuscript are available upon request.

Ethics approval and consent to participate

The series was approved via The Institutional Review Board for the King Saud University College of Medicine (E-19-3849).
Consent for publication
Consent was obtained for publication from each patient in the series.

Competing interests
The author declares that he has no competing interests.

Received: 27 May 2019 Accepted: 15 July 2019
Published online: 18 July 2019

References
1. Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al. 2010 ACCF/AHA/AATS/ACR/ASRA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with thoracic aortic disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121(13):e266–369.
2. Borger MA, Preston M, Ivanov J, Fedak PW, Davierwala P, Armstrong S, et al. Should the ascending aorta be replaced more frequently in patients with bicuspid aortic valve disease? J Thorac Cardiovasc Surg. 2004;128(5):677–83.
3. Liu S, Shi Y, Liu R, Tong M, Luo X, Xu J. Early prognosis of reduction ascending Aortoplasty in patients with aortic valve disease: a single Center’s experience. Ann Thorac Surg. 2017;103(2):S11–6.
4. Robicsek F, Cook JW, Reanes MK Jr, Skipper ER. Size reduction ascending aortoplasty: is it dead or alive? J Thorac Cardiovasc Surg. 2004;128(4):562–70.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.